iTeos Therapeutics Files 2025 Proxy Statement
| Field | Detail |
|---|---|
| Company | Iteos Therapeutics, Inc. |
| Form Type | DEF 14A |
| Filed Date | Apr 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
TL;DR
iTeos proxy out - vote your shares for the June 17th meeting!
AI Summary
iTeos Therapeutics, Inc. filed its Definitive Proxy Statement (DEF 14A) on April 24, 2025, for its annual meeting on June 17, 2025. The filing details executive compensation, board nominations, and other corporate governance matters for the fiscal year ending December 31, 2024. Key individuals mentioned include Michel Detheux and Matthew A. Call.
Why It Matters
This filing provides shareholders with crucial information regarding the company's leadership, compensation, and voting matters, enabling informed participation in corporate governance.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) and does not contain new material events or financial disclosures that would inherently increase risk.
Key Numbers
- 20250617 — Annual Meeting Date (Shareholders will vote on proposals at this date.)
- 20250424 — Filing Date (The proxy statement was filed with the SEC on this date.)
- 2024-12-31 — Fiscal Year End (The reporting period for the proxy statement's disclosures.)
Key Players & Entities
- iTeos Therapeutics, Inc. (company) — Registrant
- Michel Detheux (person) — Member
- Matthew A. Call (person) — Member
- 321 ARSENAL STREET (address) — Business and Mailing Address
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit shareholder votes on important matters such as the election of directors, executive compensation, and other corporate actions.
When is the iTeos Therapeutics, Inc. annual meeting scheduled?
The annual meeting for iTeos Therapeutics, Inc. is scheduled for June 17, 2025.
Who are some of the key individuals mentioned in the filing related to board membership?
Michel Detheux and Matthew A. Call are mentioned as members.
What is the business address of iTeos Therapeutics, Inc.?
The business address is 321 ARSENAL STREET, BLDG 312, FLOOR 3, SUITE 301, WATERTOWN, MA 02472.
What is the SIC code for iTeos Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for iTeos Therapeutics, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 24, 2025 by Michel Detheux regarding iTeos Therapeutics, Inc..